EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY-NC-ND 4.0

Sodium glycididazole combined with definitive chemoradiotherapy for patients with esophageal squamous cell carcinoma: A multicenter randomized clinical trial

Xiaoling Li iD, Hanxi Zhao, Peng Xie iD, Wanqi Zhu, Liping Liu, Peipei Wu, Yanxing Sheng, Chuandong Wang, Yipeng Song, Xiangjiao Meng iD, Jiandong Zhang, Ligang Xing

Precision Radiation Oncology · 2026-03 · 10 (1) · 19-26

DOI: 10.1002/pro6.70052 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Precision Radiation Oncology, online erschienen am 25.02.2026. Verfasst von Xiaoling Li und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences J…. Die Arbeit nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Natural Science Foundation of China, China Postdoctoral Science Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

To evaluate the efficacy and safety of the radiosensitizer‐sodium glycididazole (CMNa) combined with definitive concurrent chemoradiotherapy (CCRT) versus CCRT alone in patients with locally advanced esophageal squamous cell carcinoma (ESCC).

Methods

Patients were enrolled and randomly assigned to receive CMNa plus CCRT (CMNa group) or CCRT alone (control group). CMNa (800 mg/m 2 ) was administered three times per week during radiotherapy (1.8‐2.0 Gy per fraction, total dose of 59.4‐60.0 Gy). The primary endpoint was the objective response rate (ORR) and the secondary endpoint was the incidence of adverse events.

Results

Sixty‐six patients with ESCC were recruited from six medical centers between 2016 and 2018. The ORRs in the CMNa and control groups were 90.32% and 68.57%, respectively ( χ 2 = 4.925, p = 0.0265). The proportions of patients with a complete response were 8/31 (25.81%) and 8/35 (22.86%) in the CMNa and control groups, respectively. The combination of CMNa and CCRT did not increase the incidence of acute or late adverse effects.

Conclusion

CMNa combined with CCRT improved the ORR in patients with ESCC compared with CCRT alone without increasing treatment‐related toxicity. Trial Registration The protocol was registered at Clinicaltrials.gov ( www.clinicaltrials.gov ) (Clinical Trials ID: NCT02721563). Study Registration Date: March 29, 2016.

Schlagwörter

Stichwörter der Autor:innen

concurrent chemoradiotherapyesophageal squamous cell carcinomasodium glycididazole

Autor:innen und Institutionen

  • Department of Radiation Oncology Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences Jinan Shandong China.
  • Department of Radiology Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences Jinan Shandong China.
  • Department of Pathology Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences Jinan Shandong China.
  • Department of Radiation Oncology Jining No.1 People's Hospital Jining Shandong China.
  • Department of Radiation Oncology Liaocheng People's Hospital Liaocheng Shandong China.
  • Department of Radiation Oncology Anqiu People's Hospital Anqiu Shandong China.

ORCID-Profile: Xiaoling Li, Peng Xie, Xiangjiao Meng

Förderung

  • National Natural Science Foundation of China
  • China Postdoctoral Science Foundation

Zitieren

APA

Li, X., Zhao, H., Xie, P., Zhu, W., Liu, L., Wu, P., Sheng, Y., Wang, C., Song, Y., Meng, X., Zhang, J., & Xing, L. (2026). Sodium glycididazole combined with definitive chemoradiotherapy for patients with esophageal squamous cell carcinoma: A multicenter randomized clinical trial. Precision Radiation Oncology, 10(1), 19-26. https://doi.org/10.1002/pro6.70052

Vancouver

Li X, Zhao H, Xie P, Zhu W, Liu L, Wu P, et al. Sodium glycididazole combined with definitive chemoradiotherapy for patients with esophageal squamous cell carcinoma: A multicenter randomized clinical trial. Precision Radiation Oncology. 2026;10(1):19-26. doi:10.1002/pro6.70052

BibTeX
@article{Li2026,
  author = {Li, Xiaoling and Zhao, Hanxi and Xie, Peng and Zhu, Wanqi and Liu, Liping and Wu, Peipei and Sheng, Yanxing and Wang, Chuandong and Song, Yipeng and Meng, Xiangjiao and Zhang, Jiandong and Xing, Ligang},
  title = {Sodium glycididazole combined with definitive chemoradiotherapy for patients with esophageal squamous cell carcinoma: A multicenter randomized clinical trial},
  journal = {Precision Radiation Oncology},
  year = {2026},
  volume = {10},
  number = {1},
  pages = {19--26},
  doi = {10.1002/pro6.70052}
}
Kostenlos starten →